We are live on ! Find out more
GILD icon

Gilead Sciences

1,522 hedge funds and large institutions have $72.7B invested in Gilead Sciences in 2018 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 544 increasing their positions, 725 reducing their positions, and 107 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 78.96%79% (+0.04%)

3% less funds holding

Funds holding: 1,5631,522 (-41)

6% less capital invested

Capital invested by funds: $77.5B → $72.7B (-$4.82B)

22% less funds holding in top 10

Funds holding in top 10: 6047 (-13)

25% less repeat investments, than reductions

Existing positions increased: 544 | Existing positions reduced: 725

29% less first-time investments, than exits

New positions opened: 76 | Existing positions closed: 107

31% less call options, than puts

Call options by funds: $1.25B | Put options by funds: $1.82B

Holders
1,522
Holders Change
-41
Holders Change %
-2.62%
% of All Funds
34.84%
Holding in Top 10
47
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-21.67%
% of All Funds
1.08%
New
76
Increased
544
Reduced
725
Closed
107
Calls
$1.25B
Puts
$1.82B
Net Calls
-$567M
Net Calls Change
-$452M
Name Holding Trade Value Shares
Change
Change in
Stake
NIM
351
Needham Investment Management
New York
$11.1M -$70.6K -1,000 -0.6%
DA
352
Denali Advisors
California
$11M +$1.01M +14,300 +10%
Cambridge Investment Research Advisors
353
Cambridge Investment Research Advisors
Iowa
$11M -$629K -8,907 -5%
Jane Street
354
Jane Street
New York
$11M +$3.9M +55,247 +55%
HI
355
Honeywell International
North Carolina
$11M +$10.9M +155,000 New
FAAS
356
First Allied Advisory Services
California
$10.8M +$4.85M +68,614 +81%
BPC
357
Banque Pictet & Cie
Switzerland
$10.8M +$1.31M +18,527 +14%
DILIC
358
Dai-ichi Life Insurance Company
Japan
$10.8M -$1.17M -16,618 -10%
NPA
359
Nichols & Pratt Advisers
Massachusetts
$10.8M -$190K -2,690 -2%
Bank of Nova Scotia
360
Bank of Nova Scotia
Ontario, Canada
$10.8M -$68.8M -974,304 -87%
Mirae Asset Global Investments
361
Mirae Asset Global Investments
South Korea
$10.6M +$1.3M +18,416 +14%
MSE
362
MUFG Securities EMEA
United Kingdom
$10.5M -$12.3M -174,144 -54%
AIM
363
Assured Investment Management
New York
$10.5M -$1.16M -16,392 -10%
WF
364
Welch & Forbes
Massachusetts
$10.5M -$560K -7,927 -5%
TAM
365
Trillium Asset Management
Massachusetts
$10.4M +$5.21M +73,759 +100%
Fayez Sarofim & Co
366
Fayez Sarofim & Co
Texas
$10.4M -$1.68M -23,820 -14%
GD
367
Grandfield & Dodd
New York
$10.4M +$542K +7,670 +6%
FWIA
368
Fort Washington Investment Advisors
Ohio
$10.3M -$124K -1,763 -1%
OAM
369
Oxford Asset Management
United Kingdom
$10.3M +$9.74M +137,973 +1,831%
FAN
370
Financial Advisors Network
California
$10.3M +$10.2M +145,017 New
GIM
371
Greylin Investment Management
Virginia
$10.2M +$4.58M +64,920 +82%
Natixis Advisors
372
Natixis Advisors
Massachusetts
$10M -$905K -12,811 -8%
RPA
373
Rock Point Advisors
Vermont
$9.9M +$1.82M +25,783 +23%
UR
374
USCA RIA
Texas
$9.8M +$3.33M +47,143 +52%
CM
375
CS McKee
Pennsylvania
$9.68M -$403K -5,700 -4%

GILD Hedge Fund Activity: Q2 2018 in Review

1,522 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2018, worth a combined $72.7B — down 6.2% from $77.5B a quarter earlier.

Sellers outnumbered buyers: 107 funds closed out of GILD and 76 opened new positions — a net loss of 31 holders — while 725 trimmed existing stakes and 544 added.

The largest buyer was Capital Research Global Investors, adding an estimated $995M. The largest seller was Fidelity Investments, cutting an estimated $361M.

  • 1,522 institutional investors held Gilead Sciences (GILD) as of Q2 2018, down from 1,563 in Q1 2018.
  • Funds reported $72.7B of Gilead Sciences stock for Q2 2018, down 6.2% quarter-over-quarter.
  • 76 funds opened new Gilead Sciences positions in Q2 2018 and 107 closed out, a net change of -31 holders.
  • The largest Gilead Sciences buyer in Q2 2018 was Capital Research Global Investors, an estimated $995M added.
  • The largest Gilead Sciences seller in Q2 2018 was Fidelity Investments, an estimated $361M sold.

Based on aggregated 13F filings for Q2 2018.